Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody

@article{Renner1997TreatmentOR,
  title={Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody},
  author={Cristoph Renner and Frank Hartmann and Michael Pfreundschuh},
  journal={Cancer Immunology, Immunotherapy},
  year={1997},
  volume={45},
  pages={184-186}
}
 A group of 15 patients with refractory Hodgkin′s disease were treated in a phase I/II trial with the natural-killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fcγ receptor III (CD16 antigen) and the Hodgkin’s associated CD30 antigen. The antibody was given four times every 3 – 4 days, starting with 1 mg/m2. The treatment was well tolerated and the maximum tolerated dose was not reached at 64 mg/m2. Side-effects were rare and consisted of fever… CONTINUE READING